title: Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B.
abstract: To address the role of dimerization in the function of the monocyte chemoattractant protein-1, MCP-1, we mutated residues that comprise the core of the dimerization interface and characterized the ability of these mutants to dimerize and to bind and activate the MCP-1 receptor, CCR2b. One mutant, P8A*, does not dimerize. However, it has wild type binding affinity, stimulates chemotaxis, inhibits adenylate cyclase, and stimulates calcium influx with wild type potency and efficacy. These data suggest that MCP-1 binds and activates its receptor as a monomer. In contrast, Y13A*, another monomeric mutant, has a 100-fold weaker binding affinity, is a much less potent inhibitor of adenylate cyclase and stimulator of calcium influx, and is unable to stimulate chemotaxis. Thus Tyr13 may make important contacts with the receptor that are required for high affinity binding and signal transduction. We also explored whether a mutant, [1+9-76]MCP-1 (MCP-1 lacking residues 2-8), antagonizes wild type MCP-1 by competitive inhibition, or by a dominant negative mechanism wherein heterodimers of MCP-1 and [1+9-76]MCP-1 bind to the receptor but are signaling incompetent. Consistent with the finding that MCP-1 can bind and activate the receptor as a monomer, we demonstrate that binding of MCP-1 in the presence of [1+9-76]MCP-1 over a range of concentrations of both ligands fits well to a simple model in which monomeric [1+9-76]MCP-1 functions as a competitive inhibitor of monomeric MCP-1. These results are crucial for elucidating the molecular details of receptor binding and activation, for interpreting mutagenesis data, for understanding how antagonistic chemokine variants function, and for the design of receptor antagonists.
authors.affiliation: Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720, USA.
authors.forename: C D
authors.initials: CD
authors.lastname: Paavola
authors.forename: S
authors.initials: S
authors.lastname: Hemmerich
authors.forename: D
authors.initials: D
authors.lastname: Grunberger
authors.forename: I
authors.initials: I
authors.lastname: Polsky
authors.forename: A
authors.initials: A
authors.lastname: Bloom
authors.forename: R
authors.initials: R
authors.lastname: Freedman
authors.forename: M
authors.initials: M
authors.lastname: Mulkins
authors.forename: S
authors.initials: S
authors.lastname: Bhakta
authors.forename: D
authors.initials: D
authors.lastname: McCarley
authors.forename: L
authors.initials: L
authors.lastname: Wiesent
authors.forename: B
authors.initials: B
authors.lastname: Wong
authors.forename: K
authors.initials: K
authors.lastname: Jarnagin
authors.forename: T M
authors.initials: TM
authors.lastname: Handel
mesh_terms: D018932:Chemokine CCL2 / Q000378:metabolism*; D019281:Dimerization; D004220:Disulfides / Q000737:chemistry; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D011485:Protein Binding; D054390:Receptors, CCR2; D019707:Receptors, Chemokine; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism
chemical_list: C515334:CCR2 protein, human; D018932:Chemokine CCL2; D004220:Disulfides; D054390:Receptors, CCR2; D019707:Receptors, Chemokine; D018121:Receptors, Cytokine; D011994:Recombinant Proteins